Cathepsin-D, uuokinase plasminogen activator and type-1 plasminogen activator Inhibitor in early breast cancer: An Immunohistochemical study of prognostic value and relations to tenascin C and other factors

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 167-174

  Jahkola, T ^a   Toivonen, T ^b   Von Smitten, K ^a   Virtanen, I ^c   Wasenius, V M ^a   Blomqvist, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^c NONE

Author keywords

Breast conserving surgery; Cathepsin D; Early breast cancer; Immunohistochemistry; Local recurrence; Metastasis; PAI 1; uPA

Indexed keywords

CATHEPSIN D; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; TENASCIN; UROKINASE; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BREAST CANCER; CARCINOMA CELL; CONSERVATIVE TREATMENT; CYTOPLASM; CYTOSOL; DIAGNOSTIC VALUE; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL; BREAST TUMOR; METABOLISM; METASTASIS; MULTIVARIATE ANALYSIS; PATHOLOGY; TUMOR RECURRENCE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; TENASCIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033109360     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690336     Document Type: Article

References (55)

1. Aaltonen M, Lipponen P, Kosma V-M, Aaltomaa S and Syrjänen K (1995) Prognostic value of cathepsin D expression in female breast cancer. Anticancer Res 15: 1033-1038
2. Alo PL, Visca P, Marci A, Mangoni A, Botti C and Tondo UD (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482
3. Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L and Rosen PP (1994) Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 18: 158-166
4. Bernstein LR and Liotta LA (1994) Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 6: 106-113
5. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA and Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603
6. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
7. Cardiff RD (1994) Cathepsin D and breast cancer: useful? (editorial). Hum Pathol 25: 847-848
8. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF and Emmert-Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25: 857-862
9. Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut MN, Allasia C and Piana L (1993) Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol 170: 463-470
10. Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA and Andreasen PA (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and alfa-2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452
11. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E and Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079-1088
12. Dano K, Andreasen PA, Grondal-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266
13. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K and Osborn M (1992) Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. Am J Pathol 141: 1003-1012
14. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62: 531-533
15. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
16. Duffy MJ, Brouillet J-P, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Maudelonde T and Rochefort H (1991) Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 37: 101-104
17. Duffy MJ, Reilly D, Brouillet J-P, McDermott EWM, Faul C, O'Higgins N, Fennelly JJ, Maudelonde T and Rochefort H (1992) Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem 38: 2114-2116
18. Fernö M, Baldetorp B, Borg A, Brouillet J-P, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D and Group t.S.S.B.C. (1994) Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A: 2042-2048
19. Ferrandina G, Scambia G, Bardelli F, Panici PB, Mancuso S and Messori A (1997) Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661-666
20. Foekens JA, Schmitt M, von Putten WLJ, Peters HA, Bontenbal M, Jánicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
21. Foekens JA, Schmitt M, von Putten WLJ, Peters HA, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
22. Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A and Oglobine J (1991) Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926-932
23. Granata G, Coradini D, Cappelletti V and Fronzo GD (1991) Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27: 970-972
24. Grondal-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
25. Grondal-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brunner N (1997) Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163
26. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL and Horne CHW (1990) Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 65: 265-271
27. Hofmann R, Lehmer A, Buresch M, Hartung R and Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487-492
28. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N and Kallioniemi O-P (1993) Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11, 36-43
29. Jahkola T, Toivonen T, von Smitten K, Blomqvist C and Virtanen I (1996) Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer (Pred Oncol) 69: 445-447
30. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H and Blomqvist C (1998a) Tenascin-C expression in invasion border of early breast cancer - a predictor of local and distant recurrence. Br J Cancer 78: 1507-1513
31. Jahkola T, Toivonen T, Nordling S, von Smitten K and Virtanen I (1998b) Expression of tenascin-C in intraductal carcinoma of human breast: relation to invasion. Eur J Cancer 34: 1687-1692
32. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
33. Jänicke F, Schmitt M, Ulm K, Gössner W and Graeff H (1989) Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 334: 1049
34. Joensuu H, Toikkanen S and Isola J (1995) Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71: 155-159
35. Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P and Battifora H (1993) Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 71: 2756-2763
36. Keski-Oja J, Lohi J, Tuuttila A, Tryggvason K and Vartio T (1992) Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 202: 471-476
37. Kute TE, Shao ZM, Sugg NK, Long RT, Rusell GB and Case LD (1991) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198-5203
38. Liotta LA, Tryggvason K, Garbisa S, Robey PG and Abe S (1981) Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 20: 100-104
39. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K (1994) Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584
40. Namer M, Ramaioli A, Fontana X, Etienne M-C, Héry M, Jourlait A, Milano G, Frenay M, Francois E and Lapalus F (1991) Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 19, 85-93
41. O'Donoghue AEMA, Poller DN, Bell JA, Galea MH, Elston CW, Blamey RW and Ellis IO (1995) Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 33: 137-145
42. Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H and Rochefort H (1993) A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71: 2006-2012
43. Ravdin PM (1993) Evaluation of cathepsin D as a prognostic factor in breast cancer. (review). Breast Cancer Res Treat 24: 219-226
44. Ravdin PM, Tandon AK, Allred C, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC and Osborne CK (1994) Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467-474
45. Razumovic JJ, Stojkovic RR, Petrovecki M and Gamulin S (1997) Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat 43: 117-122
46. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ and Andreasen PA (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214
47. Rochefort H (1996) The prognostic value of cathepsin D in breast cancer. A long road to the clinic. (editorial). Eur J Cancer 32A: 7-8
48. Roger P, Montcourrier P, Maudelonde T, Brouillet J-P, Pages A, Laffargue F and Rochefort H (1994) Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 25: 863-871
49. Spyratos F, Brouillet J-P, Defrenne A, Hacene K, Rouessé J, Maudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H (1989) Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 334: 1115-1118
50. Spyratos F, Martin P-M, Hacène K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Doussal VL, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272
51. Tandon AK, Clark GM, Chamness GC, Chirgwin JM and McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302
52. Tetû B, Brisson J, Côté C, Brisson S, Potvin D and Roberge N (1993) Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429-435
53. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB and Rose C (1989) Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014
54. Westley BR and May FEB (1996) Cathepsin D and breast cancer. Eur J Cancer 32A: 15-24
55. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM and Rudland PS (1993) Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 67: 767-772